for total edwards, we expect sales of $num-one billion to $num-two billion.
for the full year year-six, we continue to expect adjusted earnings per share of $num-one to $num-two.
for the first quarter of year-six, we project total sales to be between $num-one.num-txtillion and $num-two billion and adjusted earnings per share of $num-three to $num-four.
sales in the fourth quarter were flat year-over-year on an underlying basis and adjusted earnings per share grew num-one% to $num-two versus the prior year.
gaap earnings per share was similar at $num-one.
we expect surgical structural heart sales of $num-one million to $num-two million and critical care sales of $num-three million to $num-one million.
for tavr, we expect sales of $num-one billion to $num-two billion.
as we indicated at our investor conference, we expect full year sales between $num-one billion and $num-two billion representing mid-teens underlying growth on a year-over-year basis.
in surgical structural heart, full-year year-five global sales of $num-one million decreased num-two% on an underlying basis over the prior year, in line of our guidance, with our guidance of num-three% to num-four% decline.
fourth quarter sales of $num-one million held steady with qtr-three and declined num-two% year-over-year on an underlying basis, which was below our previous expectation for positive growth.
for the full year year-five, sales increased num-one% on an underlying basis to $num-two billion, adjusted earnings per share was flat at $num-three and we generated over $num-four million of adjusted free cash flow.
full-year year-five global sales -- global tavr sales of num-one billion increased num-two% on an underlying basis over the prior year.
we now expect average diluted shares outstanding for year-six to be between num-one million and num-two million.
now turning to our quarterly results, consistent with our guidance at our investor conference last month, fourth quarter sales of $num-one billion were in line with the year ago period when edwards' grew nearly num-two% on an underlying basis, reflecting the strength, even during the ongoing pandemic.
fourth quarter global sales were $num-one million, representing sequential improvement versus qtr-three.
in critical care, full year year-five global sales of $num-one million decreased num-two% on an underlying basis versus the prior year, in line with our guidance of flat to down num-three%.